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Abstract
The investigation of dedicated contrast agents for x-ray dark-field imaging, which exploits
small-angle scattering at microstructures for contrast generation, is of strong interest in
analogy to the common clinical use of high-atomic number contrast media in conventional
attenuation-based imaging, since dark-field imaging has proven to provide complementary
information. Therefore, agents consisting of gas bubbles, as used in ultrasound imaging for
example, are of particular interest. In this work, we investigate an experimental contrast
agent based on microbubbles consisting of a polyvinyl-alcohol shell with an iron oxide coat-
ing, which was originally developed for multimodal imaging and drug delivery. Its perfor-
mance as a possible contrast medium for small-animal angiography was examined using a
mouse carcass to realistically consider attenuating and scattering background signal. Sub-
traction images of dark field, phase contrast and attenuation were acquired for a concentra-
tion series of 100%, 10% and 1.3% to mimic different stages of dilution in the contrast agent
in the blood vessel system. The images were compared to the gold-standard iodine-based
contrast agent Solutrast, showing a good contrast improvement by microbubbles in dark-
field imaging. This study proves the feasibility of microbubble-based dark-field contrast-
enhancement in presence of scattering and attenuating mouse body structures like bone
and fur. Therefore, it suggests a strong potential of the use of polymer-based microbubbles
for small-animal dark-field angiography.
Introduction
Complementary to conventional attenuation-based x-ray imaging, the generation of contrast
from refraction and scattering that occur when x-rays pass through matter has gained strong
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interest in the last decades. As one of several possible approaches, grating-based interferometry
has proven to be the most robust and practical in terms of translation from highly-brilliant x-
ray synchrotron radiation sources to laboratory-based setups with conventional polychromatic
x-ray sources, facilitating reasonable flux and relatively large fields of view [1, 2]. Therefore,
grating-based interferometry shows great potential for possible implementation into a clinical
environment, as supported by many ex vivo studies promoting improved soft-tissue contrast
and complementary information obtained from grating-based phase contrast [3–7]. While the
phase-contrast channel exploits refraction of x-rays in the sample in a range resolvable by the
grating periods, Talbot-Lau interferometry also provides information about microstructures in
the sample via an imaging channel commonly known as the dark field [2]. In contrast to fea-
ture depiction by attenuation or phase contrast, the dark-field signal even indicates structures
below the resolution limit of the imaging system by measuring the strength of ultra-small-
angle x-ray scattering in the sample [8–10]. Hence, grating-based interferometry yields three
inherently registered contrast images, i.e. the attenuation-contrast image, the phase-contrast
image and the dark-field image, each containing complementary information.
Recently, the technological developments in the area of x-ray phase-contrast and dark-field
imaging (PCI, DFI) have advanced significantly such that in vivo projection imaging of mice
has become possible [11]. Also, different issues standing in the way of translating PCI and DFI
from bench to bedside, such as PCI at high photon energies [12], interferometry using a rotat-
ing gantry [13], or the usage of bent gratings for larger cone angles [14] have been tackled or—
concerning grating manufacturing for larger fields of view—are under development. Even a
first feasibility study for a clinically applicable PCI/DFI mammography setup has been con-
ducted [15]. In the course of this general trend towards clinical applicability, naturally the ques-
tion about dedicated contrast agents for this new technology arises. In conventional
attenuation-based x-ray radiography and computed tomography (CT), the use of iodinated
contrast agents represents the gold standard for many diagnostic questions, especially for vessel
representation in projection angiography. As suggested by various applications of DFI, i.e.
representation of changes of the alveolar structure in lungs [16, 17], microcalcifications in
breast tissue [3, 18] and depiction of scattering at the trabecular structure of bones [19], an
agent consisting of many interfaces between materials of strongly different indices of refraction
is considered optimal for DFI. After the scattering properties of clinically used microbubble-
based contrast agents widely applied in ultrasound imaging [20] were first investigated using
diffraction enhanced imaging [21], we studied the potential for their use in Talbot-Lau interfer-
ometry in a preceding phantom study, confirming the ability of microbubbles to scatter x-rays
at gas-to-shell interfaces [22]. Recently, Millard et al. [23] presented a Monte-Carlo simulation
approach for a quantitative description of scattering due to bubbles. A comprehensive review
about the wide variety in composition and properties of available microbubbles and their bio-
medical applications in imaging and drug delivery is given by Sirsi et al. [24].
In this study, we present an investigation of an experimental contrast agent based on micro-
bubbles that are made up of a polyvinyl-alcohol (PVA) shell [25] with an iron-oxide coating
[26]. The agent is under development for multiple purposes, such as magnetic resonance (MR),
molecular imaging or ultrasound imaging (US) depending on the exact design parameters and
functionalization of the surface (for example [27, 28]). Biocompatibility was shown [29] and is
further supported by a recent study that successfully applies a subspecies of this new agent to
in vivo rats for MR and Single Photon Emission CT (SPECT) [28]. To mimic conditions closer
to the actual application to an animal, the PVA contrast agent was tested with the scattering
background signal provided by a mouse carcass in DFI and compared to a clinically-used
iodine-based contrast agent as a gold standard in attenuation-based imaging. Hereby, the
potential for application of microbubbles in in vivo small-animal angiography was evaluated.
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Materials and Methods
Contrast agents
Two different contrast agents were used in this study. The main focus lies on the magnetically
coated microbubbles with the notation DMM150 by Surflay Nanotec GmbH, Berlin, Germany.
The bubbles consist of a shell based on polyvinylalcohol (PVA), coated with four layers of
super paramagnetic iron oxide (Fe3O4) nanoparticles (SPION). 100% PVA bubbles suspension
corresponds to a concentration of 5 × 109 bubbles/ml; in addition, the PVA bubbles were also
measured diluted to 10% and 1.3% concentration. According to the manufacturer, the relative
magnetization of this batch corresponds to 6.95 g iron per 109 bubbles, resulting in an iron
oxide amount of 9.6 × 10−12 g per bubble. The amount of PVA per bubble is reported by the
manufacturer as 3.2 × 10−12 g. The thickness of the PVA shell lies between 400 and 600 nm.
The SPION layers are coated onto the outside of the PVA shell by covalent coupling with alter-
nating thin polyelectrolyte layers. The manufacturer determined the mean outer diameter of
the bubbles by visual inspection via a microscope of a stained batch on 20 bubbles to be
5.5 ± 0.7 μm.
For gold standard comparison, the clinically used iodine-based x-ray contrast agent Solu-
trast
1
300 (Bracco Imaging Deutschland GmbH, Konstanz, Germany) was tested, pure and
diluted to 10% volume concentration.
Setup and image acquisition
The measurements were performed at a prototype preclinical dark-field and phase-contrast
imaging scanner (developed in collaboration with Bruker microCT, Kontich, Belgium),
described in detail by Tapfer et al. [13]. The setup in the scanner consists of a Talbot-Lau inter-
ferometer, an x-ray source and a detector installed on a gantry that can be rotated around the
sample stage, facilitating in vivo imaging of small animals.
The interferometer comprises three gratings manufactured bymicroworks, Karlsruhe, Ger-
many, optimized for a design energy of 23 keV. The experimental setup was described in detail
in a previous publication by Velroyen et al. [22], and was used with an improved analyzer grat-
ing with deeper line structures (45 μm). The detector was operated in a 2×2 binning mode,
resulting in an effective pixel size of 58 μm. The x-ray source has a tungsten target and was
operated at maximum power (current of 525 μA) at the peak voltage of 35 kVp. Besides the
source and phase grating, no additonal spectral filtering was applied.
To be able to extract absorption, phase-contrast and dark-field images, phase stepping was
used [2, 30]. For a preliminary contrast comparison, a reference sample of pure water and the
pure PVA bubble suspension were measured in identical plastic vials of 4.2 mm inner diameter
(in the cylindrical part).
Each scan had 5 phase steps with 3.33 s exposure, resulting in a total exposure time of 16.65
s for one set of images of all three modalities.
For the main experiment, a mouse carcass was used to gain a proper representation of back-
ground signal in terms of bone structure and fur for contrast-agent testing. (According to the
German Animal Welfare Act, TSchG §7 subsection 2(3), sacrificing an animal for the use of its
organs or tissue for scientific purposes does not fall under the definition of an animal experi-
ment. Therefore such an ex vivo experiment as presented here does not require a dedicated eth-
ics approval.) The mouse was obtained through standard breeding and housing at Helmholtz-
Zentrum Munich. It was sacrificed by an authorized expert via CO2 overdose. To be able to
reliably locate the contrast-medium position, a plastic tube with an inner diameter of 1.6 mm
was surgically implanted underneath the peritoneum entering at the chest and exiting in the
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lower abdominal area. The tube was fixated using thin sewing threads. The experimental proto-
col used with PVA bubbles (100%, 10%, 1.3%) and Solutrast (100%, 10%) started with the
injection of 0.3 to 0.4 ml of contrast agent, so that the main part of the implanted tube was filled
with contrast medium.
In each experiment the carcass was imaged twice: once with contrast agent in the tube, and
once with water filling the tube. Both sets were taken with 10 steps and 5 s exposure time per
step. The accumulated dose corresponds to approximately 5.7 mGy for both sets together. The
dose had been determined via measurement of the dose rate at the according tube voltage
using a patient skin dosimeter (Unfors PSD, Unfors Instruments AB, Billdal, Sweden) placed
in the center of a polymer cylinder with a diameter of 3 cm as an appropriate mouse phantom.
To check that the bubbles from the measured batches are intact, a small amount was imaged
using a Zeiss Axiovert Light Microscope with 20-fold magnification lens.
Subtraction image processing
Prior to subtraction of the non-enhanced from the contrast-enhanced scan, the three comple-
mentary image signals transmission, dark-field and differential phase were extracted from the
raw phase stepping sets.
The opening of the specimen chamber and the attachment of the syringe in between the two
scans (with and without contrast agent) could introduce movement of carcass and tube. To
reduce the resulting artifacts in the subtraction images, a simple rigid registration procedure
was performed: The non-enhanced and the contrast-enhanced images were shifted relative to
each other, and, if necessary, one was slightly magnified or demagnified, to find the maximum
correlation between the two scans. After this improved registration, the non-enhanced image
was subtracted from the contrast-enhanced image so that an image only containing residual
noise and the signal created by the contrast agent was obtained.
Towards lower contrast-agent concentrations, the contrast agent signal started to enter the
regime of statistical image noise, but was still visually distinguishable. For a clearer discrimina-
tion, in addition to the raw subtraction signal, a second representation of the subtraction image
was created by further re-binning by a factor of two and additional means of noise reduction:
First, to isolate the true contrast-agent induced signal, any signal, that would appear outside of
the sample area (i.e. where the transmission is around unity) was masked out. Second, due to
the deep grating structures, the cone-beam geometry of the setup causes shadowing in regions
far from the optical axis [14] leading to fewer counts, increased noise and reduced visibility.
Thus, the areas near the left and right margins of the field of view were masked out using a visi-
bility map from a reference scan. Third, individual median-filtering was applied to reduce
noise and enhance connected areas. Subsequently the masked and median-filtered signal was
displayed by a hot color scheme superimposed on the original transmission image in the areas
where a threshold was reached. The individual parameters for filter-kernel size and threshold
were chosen based on best visual appearance and feature clarity and are as follows: PVA 100%
5 pixels squared, 0.05 threshold; PVA 10% 9 pixels squared, 0.025 threshold; PVA 1.3% 9 pixels
squared, 0.015 threshold; Solutrast 100% 5 pixels squared, 0.05 threshold; Solutrast 10% 9 pix-
els squared, 0.015 threshold.
Results
In vitro images of the magnetically coated PVA bubbles and a water reference sample are
shown in Fig 1(b) and 1(c). The PVA bubbles clearly show a stronger dark-field signal than
water. Transmission is also reduced by the coated PVA bubbles, but this reduction is not as
strong as in the dark-field signal. Note that, as common in radiology, in the presented
PVAMicrobubbles Contrast Agent for X-Ray Dark-Field Imaging
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Fig 1. Sample positioning and preliminary imaging of PVA contrast agent. (a) Mouse carcass fixated on the animal bed of a preclinical phase-contrast
and dark-field CT scanner. A plastic tube was surgically inserted underneath the peritoneum and some spare volume of the tube for flushing the contrast
agent downwards was attached to the right side of the mouse. (b) Transmission image of plastic vials containing water (left) and PVAmicrobubbles (right).
Grey values ranging from 0 to 0.35. (c) Dark-field image of plastic vials containing water (left) and PVAmicrobubbles (right). Grey values ranging from 0 to
0.75. (d) Visible-light brightfield microscopy image of PVAmicrobubbles.
doi:10.1371/journal.pone.0129512.g001
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transmission images black corresponds to high transmission and white to low transmission. In
case of dark field, black codes low scattering, whereas white depicts strong scattering. Since the
PVA bubbles had not been fixated, accumulation of the bubbles at the upper surface of the
round vial (i.e. along the vertical axis of the containers) was not averted. Because of the result-
ing inhomogeneous bubble distribution a reliable quantitative analysis of the signal cannot be
performed. However, these images serve to deliver a qualitative impression of the difference in
x-ray scattering power between pure water and coated PVA bubbles. We refrained from a fixa-
tion or gelification in order not to alter the chemical and osmotic environment and risk bubble
destruction. To check if intact bubbles are present in the sample, small amounts of the suspen-
sions were extracted and inspected via visible-light microscopy: Fig 1(d) shows intact bubbles.
The results of the subtraction imaging series are shown in Figs 2–5. As expected, the pure,
clinically available iodine-based Solutrast strongly absorbs x-rays, such that in the transmission
image in Fig 2(b) the contrast-agent filled tube is clearly visible. The subtraction image in Fig
2c shows that the signal strength is well above the noise floor. In Fig 2(a) the tube inserted
underneath the peritoneum is filled with water. Since this image was acquired after the one in
Fig 2(b), the contrast agent that was pushed onward is visible in the spare tube part positioned
next to the carcass on the left margin of the image. These left-over contrast agent portions
from prior measurements are the reason why also in some of the following subtraction images
signal enhancement can appear in this area. For the sake of completeness, Fig 2(d)–2(f) show
the differential phase signal of the measurement with water and the one with Solutrast in the
tube, as well as the subtraction image. They demonstrate that, due to the differential nature of
the phase signal, the subtraction is dominated by movement of the spare tube and evolving gas
bubbles in the intestines. Fig 2(g)–2(i) show the dark-field signal of the acquisition with water,
with pure Solutrast and their subtraction. The contrast-agent containing tube hardly shows up
in the direct dark-field image, but is visible in the subtraction image. However, the generated
dark-field signal is weaker than the transmission signal, since Solutrast is a homogeneous fluid.
In fact, the occurring reduction in visibility, which leads to the visible dark-field signal, can
most likely be attributed to beam-hardening of the x-ray spectrum. Since the visibility of the
interferometric image is strongly dependent on the energy of the x-rays, it can decrease if the
more optimal lower energies are filtered out by the sample [31], i.e. the contrast agent, resulting
in an enhanced dark-field signal.
Fig 3 shows the corresponding non-enhanced, contrast-enhanced, and subtraction images
for all three modalities for the pure, SPION-coated PVA bubbles. Contrary to the Solutrast
measurement, in the case of PVA bubbles, the dark-field signal generated by the bubbles in the
tube is sufficiently strong to clearly stand out in the contrast-enhanced dark-field image (Fig 3
(h)). The subtraction image in Fig 3(i) shows a signal strength well above the noise floor. On
the other hand, the absorption in the coated shell generates a visible signal in transmission (Fig
3(b) and 3(c)), which, however, is weaker than the dark-field signal. In fact the transmission
subtraction image is dominated by gassing in the intestines. As in Fig 2, the differential phase
signal does not show a relevant change by the contrast agent (Fig 3(d)–3(f)).
Though the pure PVA bubble contrast agent used in Fig 3(i) is not compatible with in vivo
in mice, other animals (such as e.g. rats) are tolerant to this high dose of magnetite-coated
PVA microbubbles, and images could be obtained under the assumption that the imaging sys-
tem would be fast enough to capture the first pass of a bolus injection into a large vessel. There-
fore, contrast-enhanced subtraction imaging with lower PVA bubble concentrations was
performed. Fig 4 shows the dark-field subtraction images of 100%, 10% and 1.3% PVA bubbles
concentration in comparison, as well as the respective filtered subtraction signal superimposed
on the original transmission image for an improved anatomical orientation. Although the sig-
nal strength of the contrast-agent filled tube reaches the noise level when the bubble
PVAMicrobubbles Contrast Agent for X-Ray Dark-Field Imaging
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concentration is reduced, the human eye can still discern the tube-shaped true signal from the
noise floor even for the lowest measured concentration. The overlaid and filtered signals in hot
color scheme in Fig 4(d) and Fig 4(f) show that, besides the true signal in the tube of interest,
only the signal in the spare volume of the tube, fully explicable by residual contrast agent from
the prior contrast-agent shot with higher concentration, and some smaller noise patches due to
residual motion artifacts light up in the mouse anatomy. These results indicate the feasibility of
contrast-enhanced perfusion dark-field imaging of the larger vessels in small animals.
For a complete comparison with the gold-standard iodine contrast agent, the corresponding
transmission subtraction images and the filtered, superimposed signals of the 100% and 10%
Fig 2. Measurement of pure Solutrast contrast agent.Grey value scaling is given in brackets. The first column shows the same image with the tube filled




], (g) dark field [0, 1.0]. The second columns shows the




], (h) dark field [0, 1.0].
The third column shows the subtraction of the image with contrast agent (second column) from the image with water (first column) for three different contrast




], (i) dark field [0, 0.13].
doi:10.1371/journal.pone.0129512.g002
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concentration of Solutrast are shown in Fig 5. Here, the main contribution to the residual signal
in the filtered images, besides the true signal in the tube, is due to movement of the tube and
evolving gas in the abdominal area of the mouse.
Discussion
In a preceding in vitro study on clinically established ultrasound microbubbles [22], the albu-
min-based Optison [32] had been identified as a promising candidate for contrast-enhanced
dark-field imaging. Unfortunately, a quantitatively reliable comparison between Optison and
Fig 3. Measurement of pure PVA bubbles contrast agent.Grey value scaling is given in brackets. The first column shows the same image with the tube




], (g) dark field [0, 1.0]. The second column shows





], (h) dark field [0, 1.0]. The third column shows the subtraction of the image with contrast agent (second column) from the image with water (first column) for




], (i) dark field [0, 0.3].
doi:10.1371/journal.pone.0129512.g003
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Fig 4. Dark-field signal subtraction andmultimodal images. Left column: dark-field signal subtraction images. Right column: threshold-limited, filtered
superimposition of the dark-field subtraction image (in color) on the respective original transmission image (grey values range: [0, 0.9]). (a)-(b) 100% PVA
microbubbles suspension, (c)-(d) 10% PVAmicrobubbles suspension, (e)-(f) 1.3% PVAmicrobubbles suspension.
doi:10.1371/journal.pone.0129512.g004
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the PVA bubbles, which would be of strong interest for benchmarking, was not possible,
because Optison has been taken off market and is not even available for research-only pur-
poses. It is known that microbubbles based on lipid/albumin shells are known to be less stable
than polymer-based bubbles [27], and that unfavorable osmotic conditions can effect bubble
size or even destroy them [33]. The Optison we had on stock from our previous study turned
out to have a reduced scattering power and consequently Optison is not included in this study.
Please note that the maximum concentration of PVA bubbles presented here is one order of
magnitude larger than the concentration that Optison was available at. Concentration along
with in vivo tolerance can be assumed to be of high importance in terms of contrast agent
design for dark-field imaging.
It is interesting to note that the contribution to the scatter signal that can be attributed to
the SPION coating of the PVA bubbles, which contains higher-density material, can be
assumed to be negligible. Calculations indicate that the amount of magnetite per bubble dis-
tributed over the shell is so low that the overall density difference between the shell and the sur-
rounding water is insignificant compared to the density difference between the air filling and
the shell. A detailed analysis of the contributions of different shell layers of varying materials is
Fig 5. Transmission signal subtraction images. Left column: transmission signal subtraction images. Right column: threshold-limited, filtered
superimposition of the transmission subtraction image (in color) on the respective original transmission image (grey values range: [0, 0.9]). (a)-(b) 100%
Solutrast, (c)-(d) 10% Solutrast.
doi:10.1371/journal.pone.0129512.g005
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beyond the scope of this purely experimental work and thus will be addressed in a subsequent
publication using a wave-optical simulation framework [34] to evaluate different bubble
designs based on the underlying physical principles of the dark-field signal [10, 35]. Addition-
ally, the question whether sub-structuring of the shell into more complex nanoclusters—as it is
the case for the PVA bubbles used in this work (see Fig 6)—can be a reason for the dark-field
signal increase will be approached in follow-up work.
In this work, we do not provide a quantitative comparison of absolute values of measured
dark-field signals, because measuring a reliable quantitative value of the microbubbles in a vial
is rendered extremely difficult by the fact that the bubbles float on the surface after already a
few seconds if no agitation or fixation is applied. However, since fixation changes the osmotic
environment, (partial) destruction of the bubbles and change in the true signal could not be
excluded either, thus we refrained from it.
Nevertheless, we can still draw qualitative conclusions from the measurements: The perfu-
sion-simulation experiments, where the strength of the dark-field signal generated by the
coated PVA bubbles was measured in a tube against the noise sources of an ex vivo animal, sup-
port the feasibility of contrast-enhanced dark-field angiography in small animals with
Fig 6. Transmission electronmicroscopy image of a PVAmicrobubble. The bubble is coated with iron-
oxide nanoparticles, manufactured by Surflay nanotec GmbH, Berlin, Germany. Image courtesy Johan
Härmark, School of Technology and Health, KTH Royal Institute of Technology, Sweden.
doi:10.1371/journal.pone.0129512.g006
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adequately designed microbubbles. The PVA microbubbles tested in this work with this given
setup are very likely at the edge of detectability when injected into a living animal, depending
on the dose tolerance and image acquisition speed. However, they were originally optimized
for other imaging modalities such as US, MR and molecular imaging [27, 28], and not specifi-
cally designed for dark-field imaging, for example in terms of concentration and size. Also, the
sensitivity of the setup used in this work is rather low compared to other grating based x-ray
imaging setups, due to the compactness of the interferometer on the gantry. Using a setup with
improved sensitivity, which means the ability to resolve smaller refraction angles in the phase
signal, for example by smaller grating periods or higher Talbot orders, also a stronger dark-
field signal detectability is expected. The application of alternative measurement schemes, for
example Fourier-based single-shot image acquisition [36, 37], which also provide phase and
dark-field information, but with a much shorter acquisition time, may allow for first-pass
bolus imaging before the contrast-agent is diluted beyond detectability. It is safe to say that the
imaging protocol can be improved in terms of motion artefacts of skeletal structures and the
tubes. However, when translated to the in vivo situation, breathing and cardiac motion are an
additional challenge. Subtraction imaging and adaptive filtering of the signal proved to be help-
ful tools for improved signal representation, especially for lower doses of contrast agent, and
can surely be optimized for example by widely available non-rigid registration algorithms to
tackle motion artifacts [38, 39]. The presented scans have not been optimized in terms of dose,
but the accumulated dose of 5.7 mGy is compatible with repeated in vivo studies.
Conclusion
In this work, we showed that SPION-coated PVA microbubbles in a small plastic tube generate
a sufficiently large dark-field signal in projection imaging in front of a small-animal back-
ground to be detected, even when strongly diluted. Therefore, we anticipate potential of PVA
bubbles to be used in dark-field subtraction angiography in small animals.
The complete biochemical design of a dedicated dark-field contrast-agent is beyond the
scope of this work and beyond the possibilities of our research laboratory. A future analysis
will focus on systematic simulations dedicated to find optimal bubble design parameters such
as coating, size and concentration appropriate for various setups laid out for different design
energies, as a guideline for preclinical and clinical contrast-agent development.
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